PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737340
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737340
Global Phototherapy Treatment Market to Reach US$2.4 Billion by 2030
The global market for Phototherapy Treatment estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Psoriasis Disease Treatment, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Acne Disease Treatment segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$528.3 Million While China is Forecast to Grow at 6.2% CAGR
The Phototherapy Treatment market in the U.S. is estimated at US$528.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$468.4 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.
Global Phototherapy Treatment Market - Key Trends & Drivers Summarized
Why Is Phototherapy Becoming a Mainstay in the Treatment of Dermatological and Neonatal Conditions?
Phototherapy, the medical application of specific wavelengths of light to treat physiological or dermatological disorders, has become an essential modality in modern clinical practice. Widely used to manage chronic skin diseases such as psoriasis, vitiligo, eczema, and acne, as well as neonatal jaundice, phototherapy offers a non-invasive, drug-free option that modulates immune response, promotes cellular regeneration, and reduces inflammation. The controlled exposure to ultraviolet A (UVA), UVB, or narrowband UVB light can normalize skin cell growth and stimulate repigmentation, making it effective in both hospital and outpatient settings.
In neonatal care, blue light phototherapy remains the gold standard for treating hyperbilirubinemia by converting unconjugated bilirubin into water-soluble isomers for easier excretion. This life-saving intervention has reduced the incidence of kernicterus and long-term neurological damage in newborns worldwide. With the increasing prevalence of skin conditions and rising awareness of the side effects associated with long-term steroid or systemic drug use, phototherapy is increasingly being preferred by both clinicians and patients seeking long-term, relapse-controlled management.
How Are Device Innovation and Treatment Personalization Enhancing Phototherapy Outcomes and Safety?
Technological advances in phototherapy devices have significantly improved treatment precision, safety, and patient adherence. Modern devices offer programmable UV dosage, skin-type calibration, real-time temperature monitoring, and targeted beam delivery, which minimizes overexposure and maximizes therapeutic impact. Narrowband UVB (NB-UVB) devices are now widely adopted for their ability to deliver effective treatment at lower carcinogenic risk compared to broadband UV systems. Handheld and comb devices allow for precision treatment in localized areas such as the scalp, hands, or feet.
At-home phototherapy units, backed by physician oversight and app-based compliance monitoring, are gaining popularity among patients with chronic dermatologic conditions. These devices reduce the logistical burden of frequent clinic visits, while ensuring consistent dosing protocols. Wearable light patches and LEDs tuned to specific therapeutic wavelengths are being developed for low-dose, continuous treatment with minimal disruption to daily life. Advances in photodosimetry, AI-assisted treatment planning, and skin phototype analysis are enabling personalized regimens that improve outcomes and reduce phototoxicity risks.
Which Patient Populations and Therapeutic Areas Are Driving Phototherapy Adoption Globally?
Patients with autoimmune skin diseases-such as psoriasis, vitiligo, and atopic dermatitis-represent the largest beneficiary group for phototherapy, especially when systemic medications are contraindicated or have failed. Acne patients and those with cutaneous T-cell lymphoma or polymorphic light eruption also rely on phototherapy for sustained remission. In neonatal care, phototherapy remains integral to pediatric units, particularly in resource-constrained settings where alternative treatments are limited. Additionally, mental health research is exploring phototherapy for seasonal affective disorder (SAD) and circadian rhythm regulation.
North America and Europe lead in phototherapy infrastructure and dermatology specialization, with well-established treatment protocols and insurance coverage in many jurisdictions. Asia-Pacific is seeing rapid uptake due to high incidence of vitiligo and psoriasis, growing access to dermatological care, and expanding neonatal health initiatives. In emerging economies, mobile phototherapy units and NGO-supported equipment donations are improving access in rural clinics. Rising public health focus on skin disease burden is further driving awareness, early diagnosis, and treatment accessibility across diverse geographies.
What Is Fueling Long-Term Growth and Strategic Innovation in the Phototherapy Market?
The growth in the phototherapy treatment market is driven by the rising incidence of dermatological conditions, a shift toward non-pharmacological therapies, and increasing awareness of skin health and neonatal care. With growing concerns around the long-term side effects of immunosuppressants and antibiotics, phototherapy is gaining ground as a safe, cost-effective, and repeatable treatment modality. The expansion of teledermatology and home-based care models is further accelerating patient adoption and treatment continuity.
Strategically, companies are investing in compact, AI-guided phototherapy systems with smart connectivity and adaptive dosage controls. Partnerships with dermatology clinics, hospitals, and maternal health networks are enabling large-scale deployment of both fixed and mobile units. Clinical trials investigating new wavelength combinations, photobiomodulation for wound healing, and dual-modality therapy (e.g., light + biologics) are expanding the therapeutic envelope of phototherapy. As regulatory frameworks evolve to support home-based medical technologies, phototherapy is poised to become a foundational tool in chronic disease management and personalized medicine.
SCOPE OF STUDY:
The report analyzes the Phototherapy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Disease Type (Psoriasis Disease Type, Acne Disease Type); Phototherapy Type (Blue Light Phototherapy, Red Light Phototherapy, Intense Pulsed Light Phototherapy, Other Phototherapy Types); End-Use (Hospitals End-Use, Dermatology Clinics End-Use, Homecare Settings End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 48 Featured) -
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.